COVID-19 Update

Combatting Future Viral Threats with Vaccine Advances

The COVID-19 pandemic has led to many changes in how pharmaceutical companies develop vaccines.

What’s Next for COVID-19 Vaccines and Variants?

More technologies and treatments are emerging for COVID-19—along with new variants.

Key Elements for Assay Transfer Success

Partnerships formed during the COVID-19 pandemic have provided a platform for change in assay development and transfers.

EMA Recommends Conditional Authorization for Novavax’s COVID-19 Vaccine

December 20, 2021

The agency recommended granting conditional marketing authorization for use of Nuvaxovid in people 18 years of age and older.

GSK and Vir Biotechnology’s Xevudy Gets Conditional Marketing Authorization from MHRA for COVID-19 Treatment

December 15, 2021

GlaxoSmithKline and Vir Biotechnology have received a conditional marketing authorization from MHRA for Xevudy (sotrovimab) in the treatment of COVID-19.

60 Million Doses of the COVID-19 Vaccine is Added to Moderna’s Supply Agreement with the UK

December 03, 2021

Moderna’s agreement with the UK government includes 29 million COVID-19 vaccine doses for delivery in 2022 and 31 million doses for delivery in 2023.

Accelerating Project Delivery with a Lean Alternative to DBB

December 02, 2021

Lean delivery offers a promising solution to supply and manufacturing bottlenecks by integrating project teams early on and widening the team’s field of view.

The Key Elements for Assay Transfer Success

December 02, 2021

Partnerships formed during the COVID-19 pandemic have provided a platform for change in assay development and transfers that should continue in the future.

Spinning Success? The Benefits of University Spinouts

December 02, 2021

Pharma and biotech are ruling the roost in terms of university innovation, but European spinouts are still experiencing barriers to long-term success.

Pandemic Alters Policies and Practices for Drug Development and Regulation

December 02, 2021

The need for medicines to combat COVID-19 has impacted the way regulatory agencies carry out their operations.

Samsung Biologics, GreenLight Biosciences, and Environmental Impact Acquisition Corp to Build mRNA Vaccine Manufacturing Capacity

November 29, 2021

Samsung Biologics, GreenLight Biosciences, and Environmental Impact Acquisition Corp. have partnered to advance GreenLight’s mRNA COVID-19 vaccine candidate.

Vaccine Makers Seek to Address Omicron SARS-CoV-2 Variant

November 29, 2021

The companies are testing their existing vaccines against the new variant of concern and are pursuing variant-specific versions.

EMA Recommends Pfizer and BioNTech’s COVID-19 Vaccine for Children

November 29, 2021

The Comirnaty vaccine received a positive opinion from the EMA’s CHMP for children five to under 12 years of age.